Edition:
United Kingdom

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

5.95USD
7:09pm GMT
Change (% chg)

$0.25 (+4.39%)
Prev Close
$5.70
Open
$5.75
Day's High
$6.07
Day's Low
$5.75
Volume
31,750
Avg. Vol
46,054
52-wk High
$14.00
52-wk Low
$4.90

Latest Key Developments (Source: Significant Developments)

Minerva Neurosciences reports Q3 loss per share $0.28
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates.Q3 loss per share $0.28.Q3 earnings per share view $-0.00 -- Thomson Reuters I/B/E/S.Minerva Neurosciences Inc - ‍expects cash, cash equivalents and marketable securities will be sufficient to fund operations for at least next 12 months​.Minerva Neurosciences Inc - ‍cash, cash equivalents, marketable securities as of Sept 30, were about $143.3 million, compared to $83.0 million as of Dec 31, 2016​.  Full Article

Minerva Neurosciences Q3 loss per share $0.24
Thursday, 3 Nov 2016 

Minerva Neurosciences Inc : Minerva Neurosciences - intend to meet with FDA to determine late stage clinical strategy, specifically design of next clinical trials with MIN-101 . Minerva Neurosciences Inc - objective is to initiate trials for min-101 in mid-2017 . Minerva neurosciences reports third quarter 2016 financial results and business updates .Q3 loss per share $0.24.  Full Article

Minerva Neurosciences reports quarterly loss per share $0.18
Thursday, 4 Aug 2016 

Minerva Neurosciences Inc : Quarterly loss per share of $0.18 .Expects that its cash, cash equivalents and marketable securities on hand at June 30, 2016 will be sufficient to fund its operations into 2018.  Full Article

Minerva Neurosciences prices of public offering of common stock
Tuesday, 14 Jun 2016 

Minerva Neurosciences Inc :Minerva Neurosciences announces pricing of public offering of common stock.  Full Article

Minerva Neurosciences announces proposed public offering of common stock
Monday, 13 Jun 2016 

Minerva Neurosciences Inc : Minerva Neurosciences announces proposed public offering of common stock .Intends to use net proceeds to fund part of continued clinical development of Min-101, Min-117, Min-202 and Min-301.  Full Article

Minerva neurosciences announces proposed public offering of common stock
Monday, 13 Jun 2016 

Minerva Neurosciences Inc : Minerva neurosciences announces proposed public offering of common stock .Intends to use net proceeds from offering, to fund part of continued clinical development of MIN-101, MIN-117, MIN-202 and MIN-301.  Full Article

Minerva Neurosciences Inc says positive top line results from phase ib clinical trial in major depressive disorder with min-202
Friday, 11 Mar 2016 

Minerva Neurosciences Inc:Announces positive top line results from phase ib clinical trial in major depressive disorder with min-202.Min-202 was observed to be well tolerated by study participants over a one-month treatment duration.  Full Article

Minerva Neurosciences, Inc announces top line data From MIN-202 Phase I Clinical Study in Japanese Patients
Monday, 1 Feb 2016 

Minerva Neurosciences, Inc:Minerva Neurosciences announces top line data from min-202 phase i clinical study in Japanese patients.Says single dose morning administration of min-202 was well tolerated at all three dose levels tested.Says no clinically relevant safety concerns were observed based on the assessment of multiple safety endpoints.  Full Article

Minerva Neurosciences Inc announces favorable top line results from min-202 phase 2a clinical trial
Monday, 11 Jan 2016 

Minerva Neurosciences Inc:Announces favorable top line results from min-202 phase 2a clinical trial in insomnia disorder.Patients treated with min-202 in the phase 2a trial were observed to have statistically significant improvements in key sleep parameters.No serious adverse events were observed in trial, and preliminary data indicate that min-202 was well tolerated by patients.Says top line data for a phase 1b trial with min-202 are expected in the first quarter of 2016.  Full Article

Minerva Neurosciences announces update on MIN-101 Clinical Development Program
Tuesday, 29 Dec 2015 

Minerva Neurosciences Inc:Announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for MIN-101.Topline results from the core 12-week treatment evaluation period are expected in the second quarter of 2016.  Full Article

BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28

* Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates